Drug Development Phase 2
The Drug Development Phase 2 module (formerly titled Phase 2 Studies) is part of the DIA Drug Development and Lifecycle Management eLearning Program. In this module, learners will learn about the factors that drive the design and conduct of phase 2 clinical trials, as well as the activities and functional areas that contribute to a successful phase 2 program.
Estimated time to complete module: 1.25 hours
This eLearning module can be purchased individually or as part of the Drug Development and Lifecycle Management eLearning Program.
- Objectives and Key Players
- Regulatory Activities
- Clinical R&D and Biostatistics Activities
- Case Study Part 1
- End of Phase 2
- Case Study Part 2
Who should attend?
This module is designed for individuals who are new to, or changing roles in, the pharmaceutical and biotechnology industries. The module will also benefit professionals who work in the areas of:
- Clinical Research
- Project Management
- Administrative Support
- Quality Assurance
- Regulatory Affairs
- Medical writing
- Business Support
Upon completion of this module, learners should be able to:
- Outline the key objectives and activities of phase 2
- Describe the regulatory activities and decisions that occur during phase 2
- Explain risk-return decisions involved in phase 2